Precision Biosciences (DTIL) Total Non-Current Liabilities (2020 - 2026)

Precision Biosciences (DTIL) has 7 years of Total Non-Current Liabilities data on file, last reported at $45.0 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $45.0 million, down 39.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $45.0 million (down 39.92% YoY), and the FY2025 annual result was $46.5 million, down 33.61% from the prior year.
• Total Non-Current Liabilities eased to $45.0 million in Q1 2026 per DTIL's latest filing, from $46.5 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $193.9 million in Q2 2022 and troughed at $45.0 million in Q1 2026.
• A 5-year average of $111.0 million and a median of $101.7 million in 2022 frame the typical range for Total Non-Current Liabilities.
• On a YoY basis, Total Non-Current Liabilities climbed as much as 62.19% in 2022 and fell as far as 49.93% in 2022.
• A 5-year view of Total Non-Current Liabilities shows it stood at $177.5 million in 2022, then decreased by 26.26% to $130.9 million in 2023, then slumped by 46.54% to $70.0 million in 2024, then slumped by 33.61% to $46.5 million in 2025, then decreased by 3.2% to $45.0 million in 2026.
• Business Quant data shows DTIL's Total Non-Current Liabilities at $45.0 million in Q1 2026, $46.5 million in Q4 2025, and $72.8 million in Q3 2025.